An Israeli medical startup Kailo Pharma is trying to change how post-traumatic stress disorder is treated, not by focusing only on symptoms, but by going after a brain mechanism believed to drive the force of traumatic memories themselves.
Kailo Pharma has raised NIS 6.5 million, roughly $2.1 million, to push forward a treatment program built around research from the University of Haifa. The company is backed by Carmel, the university’s technology transfer company, and venture fund NGT Healthcare II, with the latest funding round led by NGT and supported by the Israel Innovation Authority.
The science behind the startup’s pitch is what makes it notable. Researchers Dr. Iris Reuveni and Prof. Edi Barkai at the University of Haifa identified what they describe as a previously unknown brain mechanism tied to the pathological amplification of fear memories. Working with Prof. Chaim Gillon of the Hebrew University, the team is developing a peptide intended to block that mechanism.
That is a different proposition from the way PTSD is usually treated today. Most existing approaches are built around managing symptoms through psychiatric drugs and face-to-face psychological therapy. Kailo Pharma’s approach aims to intervene at the neurological level, targeting the process believed to intensify traumatic memory rather than simply calming its after-effects.
The proposed treatment is being developed as a nasal spray, a route chosen to help the peptide reach the central nervous system directly. In practical terms, the idea is to weaken the abnormal intensity of traumatic recall without interfering with ordinary memory.
That distinction is central to the company’s promise. Traumatic memory, in this line of research, is not being described as just a stronger version of normal memory. Instead, it behaves like an amplifier of neural activity, effectively doubling the strength of the signal.
Researchers say that unlike normal memory formation, which alters only some synaptic connections, traumatic memory changes all synaptic connections in the affected neurons. That may help explain why flashbacks, nightmares and intrusive recall can remain so persistent over time.
The startup’s most ambitious claim is that this amplification mechanism appears to operate only in neurons linked to traumatic memories, not in those responsible for normal memories. If that continues to hold up in future studies, it could offer a rare balance in PTSD care: reducing the pathological burden of trauma without erasing memory itself.
That would also set it apart from more aggressive memory-targeting approaches, which have long raised concerns about unintended damage to other memories or fragmented recall. Another potential advantage is timing. Treatments that depend on very early intervention after a traumatic event often face practical limitations. A therapy that targets the amplification mechanism could, in theory, remain useful long after the original trauma.
For now, Kailo Pharma remains at an early stage. The company plans to carry out further trials in mice over the next few years to refine dosage and strengthen statistical validation. Human clinical trials are expected to begin in around three years. Commercialization, if the science continues to succeed, could still take five to ten years.
That leaves the company in a familiar place for deep-science health startups: long on promise, still waiting on proof. But the size of the need is undeniable. PTSD is estimated to affect around 300 million people globally, and the limitations of current treatment options leave plenty of room for new approaches that are both more precise and more durable.
Kailo Pharma’s wager is simple, even if the biology is not: traumatic memory may be treatable as a distinct brain process rather than only as a lifelong psychological scar. Whether that idea becomes a viable drug will depend on what future trials show. But as an early-stage scientific bet, it is one that could draw serious attention across neuropsychiatry and trauma medicine.
Also Read: Have You Bought Noice Without Knowing It’s Swiggy’s?
